AtriCure (NASDAQ:ATRC) Updates FY 2025 Earnings Guidance

Key Points

• AtriCure has updated its FY 2025 earnings guidance, projecting an EPS of -0.390 to -0.340 and revenue between $527.0 million and $533.0 million.
• The stock is currently rated as a Moderate Buy by analysts, with a consensus target price of $50.67, despite recent downward adjustments from firms like UBS and Needham.
• AtriCure's shares experienced a decline of 4.5%, trading at $31.73, following the earnings guidance announcement.

AtriCure (NASDAQ:ATRC - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of -0.390--0.340 for the period, compared to the consensus estimate of -0.530. The company issued revenue guidance of $527.0 million-$533.0 million, compared to the consensus revenue estimate of $522.9 million.

Analysts Set New Price Targets

ATRC has been the subject of several research analyst reports. BTIG Research set a $54.00 target price on shares of AtriCure in a research note on Wednesday. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday. UBS Group reduced their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. JMP Securities reaffirmed a "market outperform" rating and issued a $60.00 price target on shares of AtriCure in a report on Wednesday, April 30th. Finally, Wall Street Zen raised AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AtriCure presently has an average rating of "Buy" and an average target price of $50.89.

AtriCure Trading Down 2.0%

ATRC traded down $0.69 on Friday, reaching $34.41. 730,309 shares of the company traded hands, compared to its average volume of 607,416. The company has a market cap of $1.70 billion, a P/E ratio of -44.69 and a beta of 1.56. The company has a quick ratio of 2.88, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. AtriCure has a one year low of $20.20 and a one year high of $43.11. The firm has a fifty day simple moving average of $32.36 and a two-hundred day simple moving average of $34.32.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%. The firm had revenue of $136.14 million during the quarter, compared to analyst estimates of $130.17 million. During the same quarter in the previous year, the business earned ($0.17) earnings per share. AtriCure's quarterly revenue was up 17.1% on a year-over-year basis. As a group, equities research analysts expect that AtriCure will post -0.6 earnings per share for the current year.

Insider Activity at AtriCure

In related news, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total value of $83,600.00. Following the completion of the sale, the insider directly owned 73,550 shares in the company, valued at $2,459,512. The trade was a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On AtriCure

Hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in AtriCure during the first quarter valued at approximately $158,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company's stock valued at $908,000 after acquiring an additional 1,230 shares in the last quarter. AQR Capital Management LLC boosted its position in AtriCure by 1.0% during the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company's stock valued at $2,700,000 after acquiring an additional 837 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company's stock valued at $3,254,000 after acquiring an additional 87,553 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company's stock worth $27,830,000 after acquiring an additional 8,956 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.